NewcelX (NCEL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.50, -12.28% vs the prior close of $2.85.
- Volume 23.08K shares, 2.9x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NCEL slides 12.3% to $2.50, a 6-month low on 2.9x normal volume. Closed at $2.50, -12.28% vs the prior close of $2.85. Day range $2.36–$3.14, opened at $2.77.
NCEL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — NCEL slides 12.3% to $2.50, a 6-month low on 2.9x normal volume
- Closed at $2.50, -12.28% vs the prior close of $2.85. Day range $2.36–$3.14, opened at $2.77.
- Volume was 23.08K shares, 2.9x its 50-day average of 8.05K — unusually heavy trading.
- Price is -20.9% vs its 50-day average ($3.16) and -18.9% vs its 200-day average ($3.08).
- 52-week range $1.83–$17.40; today's close sits at 4% of that range, 85.6% below the 52-week high.
Oct 15, 2026 — NCEL jumps 9.2% to $2.85
- Closed at $2.85, +9.20% vs the prior close of $2.61. Day range $2.61–$2.90, opened at $2.61.
- Volume was 5.90K shares, 0.7x its 50-day average of 8.05K.
- Price is -10.3% vs its 50-day average ($3.18) and -7.5% vs its 200-day average ($3.08).
- 52-week range $1.83–$18.10; today's close sits at 6% of that range, 84.3% below the 52-week high.
Oct 14, 2026 — NCEL slides 8.1% to $2.61, a 3-month low, 4 down days in a row
- Closed at $2.61, -8.10% vs the prior close of $2.84. Day range $2.61–$2.87, opened at $2.80.
- Volume was 9.30K shares, 1.2x its 50-day average of 7.97K.
- Price is -18.2% vs its 50-day average ($3.19) and -15.2% vs its 200-day average ($3.08).
- 52-week range $1.83–$18.40; today's close sits at 5% of that range, 85.8% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — NCEL dips 2.2% to $2.84, a 3-month low, 3 down days in a row
- Closed at $2.84, -2.20% vs the prior close of $2.90. Day range $2.80–$3.28, opened at $2.83.
- Volume was 5.40K shares, 0.7x its 50-day average of 8.19K.
- Price is -11.4% vs its 50-day average ($3.21) and -7.7% vs its 200-day average ($3.08).
- 52-week range $1.83–$18.52; today's close sits at 6% of that range, 84.7% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — NCEL slides 4.6% to $2.90
- Closed at $2.90, -4.63% vs the prior close of $3.05. Day range $2.90–$2.96, opened at $2.96.
- Volume was 1.20K shares, 0.1x its 50-day average of 8.37K — lighter than usual.
- Price is -9.8% vs its 50-day average ($3.22) and -5.6% vs its 200-day average ($3.07).
- 52-week range $1.83–$18.60; today's close sits at 6% of that range, 84.4% below the 52-week high.
Oct 9, 2026 — NCEL dips 2.1% to $3.05
- Closed at $3.05, -2.09% vs the prior close of $3.11. Day range $3.02–$3.08, opened at $3.02.
- Volume was 1.30K shares, 0.2x its 50-day average of 8.54K — lighter than usual.
- Price is -5.7% vs its 50-day average ($3.23) and -0.9% vs its 200-day average ($3.07).
- 52-week range $1.83–$19.07; today's close sits at 7% of that range, 84.0% below the 52-week high.
Oct 8, 2026 — NCEL rises 2.5% to $3.11, 4 up days in a row
- Closed at $3.11, +2.47% vs the prior close of $3.04. Day range $2.89–$3.11, opened at $2.92.
- Volume was 7.30K shares, 0.9x its 50-day average of 8.58K.
- Price is -3.9% vs its 50-day average ($3.24) and +1.3% vs its 200-day average ($3.07).
- 52-week range $1.83–$19.07; today's close sits at 7% of that range, 83.7% below the 52-week high.
- That makes 4 straight gains.
Oct 7, 2026 — NCEL rises 2.5% to $3.04, 3 up days in a row
- Closed at $3.04, +2.50% vs the prior close of $2.96. Day range $2.97–$3.04, opened at $3.04.
- Volume was 1.50K shares, 0.2x its 50-day average of 8.74K — lighter than usual.
- Price is -6.5% vs its 50-day average ($3.24) and -1.1% vs its 200-day average ($3.07).
- 52-week range $1.83–$19.30; today's close sits at 7% of that range, 84.3% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — NCEL jumps 3.5% to $2.96
- Closed at $2.96, +3.53% vs the prior close of $2.86. Day range $2.92–$3.20, opened at $2.99.
- Volume was 7.20K shares, 0.8x its 50-day average of 8.74K.
- Price is -9.0% vs its 50-day average ($3.25) and -3.4% vs its 200-day average ($3.07).
- 52-week range $1.83–$19.80; today's close sits at 6% of that range, 85.0% below the 52-week high.
Oct 5, 2026 — NCEL rises 0.4% to $2.86
- Closed at $2.86, +0.35% vs the prior close of $2.85. Day range $2.82–$2.86, opened at $2.82.
- Volume was 4.10K shares, 0.5x its 50-day average of 8.78K — lighter than usual.
- Price is -12.4% vs its 50-day average ($3.27) and -6.7% vs its 200-day average ($3.06).
- 52-week range $1.83–$21.30; today's close sits at 5% of that range, 86.6% below the 52-week high.
Oct 2, 2026 — NCEL dips 2.1% to $2.85, a 3-month low
- Closed at $2.85, -2.06% vs the prior close of $2.91. Day range $2.79–$2.87, opened at $2.83.
- Volume was 3.00K shares, 0.3x its 50-day average of 8.98K — lighter than usual.
- Price is -13.2% vs its 50-day average ($3.28) and -7.0% vs its 200-day average ($3.07).
- 52-week range $1.83–$21.50; today's close sits at 5% of that range, 86.7% below the 52-week high.
NCEL latest news & SEC filings
Every SEC filing by or about NCEL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 22, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 18, 2026 · Form POS AM — POS AM filing
POS AM filing
Sep 18, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 26, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 20, 2026 · Form F-3 — F-3 filing
F-3 filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 3, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 31, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 15, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 1, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jun 30, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade NCEL
- How much it moves: over the last 20 sessions the average daily move was 3.88% (largest 12.3%). That is a volatile stock.
- Liquidity: about 6.14K shares (≈$15.35K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.50 vs a range of $1.83–$17.40 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Oct 31, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 0 sales; latest: Michel Revel bought 54,545 shares on Apr 27, 2026.
- Latest filings: 6-K Sep 18, 2026; 6-K Aug 3, 2026; 6-K Jul 31, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NCEL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.77 | 3.14 | 2.36 | 2.50 | 23.08K |
| Oct 15, 2026 | 2.61 | 2.90 | 2.61 | 2.85 | 5.90K |
| Oct 14, 2026 | 2.80 | 2.87 | 2.61 | 2.61 | 9.30K |
| Oct 13, 2026 | 2.83 | 3.28 | 2.80 | 2.84 | 5.40K |
| Oct 12, 2026 | 2.96 | 2.96 | 2.90 | 2.90 | 1.20K |
| Oct 9, 2026 | 3.02 | 3.08 | 3.02 | 3.05 | 1.30K |
| Oct 8, 2026 | 2.92 | 3.11 | 2.89 | 3.11 | 7.30K |
| Oct 7, 2026 | 3.04 | 3.04 | 2.97 | 3.04 | 1.50K |
| Oct 6, 2026 | 2.99 | 3.20 | 2.92 | 2.96 | 7.20K |
| Oct 5, 2026 | 2.82 | 2.86 | 2.82 | 2.86 | 4.10K |
| Oct 2, 2026 | 2.83 | 2.87 | 2.79 | 2.85 | 3.00K |
| Oct 1, 2026 | 2.82 | 2.95 | 2.76 | 2.91 | 5.20K |
| Sep 30, 2026 | 3.22 | 3.25 | 3.00 | 3.08 | 2.70K |
| Sep 29, 2026 | 2.85 | 2.97 | 2.79 | 2.97 | 3.10K |
| Sep 28, 2026 | 2.87 | 3.02 | 2.76 | 2.92 | 7.20K |
| Sep 25, 2026 | 2.99 | 3.21 | 2.95 | 2.95 | 4.80K |
| Sep 24, 2026 | 2.89 | 2.90 | 2.76 | 2.89 | 4.20K |
| Sep 23, 2026 | 2.91 | 3.09 | 2.76 | 2.86 | 9.30K |
| Sep 22, 2026 | 2.96 | 3.37 | 2.90 | 3.04 | 4.70K |
| Sep 21, 2026 | 3.23 | 3.24 | 2.90 | 2.97 | 12.30K |
About NewcelX
NewcelX (NCEL) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in ZURICH. State of incorporation: Switzerland. Fiscal year ends December 31. SEC CIK 1783036.
NCEL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Tamar Galili | Director | Mar 18, 2026 |
| Eran Israel Iohan | Director | Mar 18, 2026 |
| Liora Oren | Director | Mar 18, 2026 |
| Michel Revel | CSO and Director | Apr 29, 2026 |
| Olivier Samuel | Director | Apr 29, 2026 |
| Ronen Twito | Chairman and CEO | Mar 18, 2026 |
| Alexander Zwyer | Director | Mar 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Omri Hagai | Chief Financial Officer | Mar 18, 2026 |
| Kfir Molakandov | VP of R&D | Mar 18, 2026 |
| Michel Revel | CSO and Director | Apr 29, 2026 |
| Ronen Twito | Chairman and CEO | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 27, 2026 | Michel Revel | Buy | 54,545 | $2.75 |
| Apr 27, 2026 | Michel Revel | Buy | 54,545 | $2.75 |
| Apr 27, 2026 | Michel Revel | Buy | 54,545 | $2.75 |
| Apr 27, 2026 | Michel Revel | Buy | 54,545 | $2.75 |
| Apr 27, 2026 | Olivier Samuel | Buy | 81,818 | $2.75 |
| Apr 27, 2026 | Olivier Samuel | Buy | 81,818 | $2.75 |
| Apr 27, 2026 | Olivier Samuel | Buy | 81,818 | $2.75 |
| Apr 27, 2026 | Olivier Samuel | Buy | 81,818 | $2.75 |
NCEL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
NCEL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NCEL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.